Today, the U.S. government announced launching a phase 1 clinical trial for a vaccine candidate to prevent Lassa Fever. The National Institutes of Health (NIH) says preventing illness through vaccination is a critical goal in reducing the disease burden from Lassa outbreaks.
This new NIH-sponsored clinical trial has begun enrolling participants in a novel, first-in-human Lassa fever vaccine study at the University of Maryland School of Medicine, Baltimore.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
